Bladder Cancer Vaccines

Bladder Cancer - Creative Biolabs Creative Biolabs is a world leader in the field of cancer vaccine development. With our extensive experience and advanced platform, we are therefore confident in offering the best services for vaccine development against bladder cancer and guarantee the finest results for our customers all over the world.

Bladder Cancer

Bladder cancer is any of several cancers that start from urinary bladder tissues. It is a condition where cells grow abnormally and have the potential to spread to other parts of the body. The most common type is transitional cell carcinoma. Other types include squamous cell carcinoma and adenocarcinoma. Risk factors include family history, smoking, frequent bladder infections, prior radiation therapy, and exposure to certain chemicals. Treatments depend on the stage of the cancer and include some combination of surgery, radiotherapy, chemotherapy or immunotherapy. And surgical options may include transurethral resection, partial or complete resection of the bladder or urinary diversion.

Therapeutic Vaccines for Bladder Cancer

Historically, immunotherapy in bladder cancer was limited to local intravesical therapy with BCG vaccine for patients with nonmuscle invasive bladder cancer. BCG is a live attenuated vaccine of Mycobacterium bovis that was initially developed in the early 1900s as a vaccine against tuberculosis. It was later observed that patients with tuberculosis actually had lower rates of cancer and subsequently hypothesized that mycobacteria might possess either direct antitumor effects or tumor suppressor properties. The antitumor effect of BCG is not cytotoxic in nature but rather a multifaceted and sustained activation of the local immune system. BCG was then investigated as a potential immunotherapy in multiple cancers but had not demonstrated consistent results. In urothelial carcinoma, however, the role of BCG was confirmed with two early randomized trials demonstrating a decrease in tumor recurrence in patients receiving intravesical BCG.

IFNα has been extensively studied in combination with BCG for the treatment of superficial bladder cancers. As the helper T cell-1 (Th1) response in the bladder is critical to BCG efficacy, the rationale for this combination rests in the enhanced Th1 stimulation with IFNα, which can augment the immune response to BCG. Patients with BCG-refractory disease or post-BCG relapse may potentially benefit from the addition of IFNα to BCG, though many of these patients are considered for cystectomy to prevent progression of the disease.

Creative Biolabs is a leader in the field of vaccine development and has focused on the cancer vaccines for years. We have experts who are able to help you with the development of the bladder cancer vaccines. If you are interested in our services, please contact us for more details.


Our services are for research use only. We do not provide services directly to individuals.

Online Inquiry

Name:
*Phone:
*E-mail Address:
*Products or Services Interested:
Project Description:
*Verification Code:
Verification code
Click image to refresh the verification code.

CONTACT US

USA
45-1 Ramsey Road, Shirley, NY 11967, USA
Tel: 1-631-381-2994
Fax: 1-631-207-8356
Email:


Follow us on

facebook   twitter   linked   blog

Shopping Basket